Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Novalead Pharma says...

    Novalead Pharma says 42 existing drugs can help in treating coronavirus patients

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-04-01T10:00:00+05:30  |  Updated On 1 April 2020 10:00 AM IST
    Novalead Pharma says 42 existing drugs can help in treating coronavirus patients

    Mumbai: Novalead Pharma on Tuesday said it has found that 42 existing drugs can be helpful in treating patients at different stages of coronavirus infection.

    The conclusions of the startup, which is backed by Tata Capital Healthcare Fund, are based on a study of 2,100 approved drugs and 30 potential viral and human targets.

    "The major advantage with this approach is that the drugs being approved are already proved to be safe for humans, are being actively manufactured and therefore can be immediately put to use in a very short time," the company's chief executive Supreet Deshpande said in a statement.

    The Pune-based company, which is into the field of drug repurposing, deployed its computational technology for identifying existing drugs that may be potentially effective against the SARS-Cov2 virus (coronavirus) as well as for minimizing the impact on the human body, as per the statement.

    Till now, there is no drug or vaccine that has been developed against the coronavirus infection, a major reason for a high number of fatalities across the world.

    "The fight against COVID-19 is a race against time and we are deploying whole of our computational infrastructure and technology platform armed with Artificial Intelligence (AI) and uses Machine Learning (ML) techniques, along with intensive statistical modeling and simulations," Deshpande said.

    The company said that in the past, it has helped in developing drugs for diabetes and psoriasis.

    "We have completed three phases of rational computational screenings and our discoveries so far include drugs that show promise as an effective treatment either by directly attacking the virus proteins or by empowering the human proteins to minimize its spread," the company's head of research Sudhir Kulkarni said.

    He also said the company would continue with its research efforts and shortlist candidates who are at different stages of coronavirus infection, including those suffering from Acute Respiratory Distress Syndrome (ARDS) stage.

    Read also: South Korean coronavirus test kit makers win USFDA pre-approval

    novalead-pharmacoronaviruscovid-19
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok